Create accountLogin

Recent searches

No recent searches

Search options

Not available on dice.camp.
dice.camp is one of the many independent Mastodon servers you can use to participate in the fediverse.
A Mastodon server for RPG folks to hang out and talk. Not owned by a billionaire.

Administered by:

Server stats:

1.8K
active users

dice.camp: AboutProfiles directoryPrivacy policy

Mastodon: AboutGet the appKeyboard shortcutsView source codev4.3.7

#drugdevelopment

1 post1 participant0 posts today
Public
Thomas Sandmann

This 2015 article provided me with food for thought this week "Why is it hard to terminate failing projects in pharmaceutical R&D?" nature.com/articles/nrd4725 (pay walled, unfortunately). It does a great job summarizing why it is so hard for teams and individuals to stop projects - despite clear opportunity costs and the high failure rate in drug development. The authors suggest 7 concrete steps toward a quick-kill strategy: #Biotech #DrugDevelopment #Science

Plan for implementing quick-kill strategies « Abandon denialism. Progression-seeking behaviour incurs massive opportunity costs. Focusing on cycle- time reduction in the past meant the industry became really slick at delivering projects that were terminated in later-stage development. « Banish ‘success’ and ‘failure’ from the organizational lexicon. Good decisions — either to progress a market- able product or to terminate an unmarketable product — are all successes. Learn from both kinds. « Rebuild reward systems to reward good decisions rather than good outcomes. « Place project progression targets in a quality frame- work, or abandon them altogether. Targets encourage progression-seeking behaviour and invite gaming of the system, and they do not work in isolation. « Quantify and communicate opportunity costs in the organization. Reframe progression-seeking behaviour in terms of opportunity costs and consider termination decisions as prospective gains rather than losses. « Overhaul feedback systems, in order to allow staff to learn the outcome of early development decisions and avoid repeating the same mistakes. « Develop a communication plan for staff and share- holders that presents the new model and the probable timescales. Communication with the financial markets is particularly important. Is this plan achievable? In our view, it has to be, as continuing to carry the cost of late-stage attrition is too great a burden to the industry and to society.
Public
Flo

Here's an interview with Grigory Khimulya on how we got from vaccine idea to clinic in 6 months at Alvea!
Some highlights:
- Debunking the meme of regulatory red tape that slows innovation
- Lean team instead of siloed departments
- Automation of paperwork where possible
- Look at all vendors in the world, find the best ones and optimize their internal processes as well to fix your bottlenecks

statecraft.pub/p/how-to-speedr

Statecraft · How to Speedrun a New Drug ApplicationBy Santi Ruiz
#drugdevelopment#biotech#vaccines
Public *
Rhyothemis

@inkican

Interesting, but the article is frustratingly vague about the mechanism of action.

The drug/MoA is probably the same as in this article⬇️
"PnPP-19 potentiates erection, in vivo and ex vivo, via NO/cGMP pathway, does not affect sodium channels or rat heart, and shows no toxicity and low immunogenicity, what makes it a very promising candidate as a novel drug in the therapy of erectile dysfunction."

dx.doi.org/10.1016/j.juro.2015

~
NO is antimicrobial and it's possible this drug could be used for other purposes.

#NitricOxide#cGMP#vasodilators
Public
Thiago Carvalho

"On Tuesday, an international team announced in the journal Cell that they had identified a potential new antibiotic lurking unnoticed in the sandy soil of North Carolina. The compound, called clovibactin, employs an unusual method of killing bacteria that makes it tough for targets to develop resistance. While clinical trials in humans are several years away, the finding is a glimmer of hope in an increasingly drug-resistant world."

#microbiology #antibioticresistance #antibiotics #drugdevelopment

ft.com/content/a8d62524-3f3f-4

Financial TimesNew bacterial ‘dark matter’ offers hope for a drug-resistant worldBy Anjana Ahuja
Public
Thiago Carvalho

"The Food and Drug Administration on Friday approved the first pill for postpartum depression, a milestone considered likely to increase recognition and treatment of a debilitating condition that afflicts about a half-million women in the United States every year."
nytimes.com/2023/08/04/health/

In April I wrote about how this new class of drugs were developed for #NatureMedicine. Read it at the link below:

nature.com/articles/d41591-023

#ScienceCommunication#DrugDevelopment#PostPartum
Public
Thiago Carvalho

I wrote about RSV vaccines in my #NatureMedicine column in February.
Very good news this week with the FDA approval of GSK's RSV vaccine for adults 60 and over - it's the first approved RSV vaccine.

edition.cnn.com/2023/05/03/hea

Several other candidate RSV vaccines are at a late stage of development, including mRNA based vaccines. The next big thing to watch for are those seeking to protect newborns and infants by maternal immunisation.

#RSV #Vaccine #RespiratoryVirus #drugdevelopment #Pharma #Immunology

nature.com/articles/d41591-023

ExploreLive feeds
About